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Ethnicity-Dependent and 
-Independent Heterogeneity in 
Healthy Normal Breast Hierarchy 
Impacts Tumor Characterization
Harikrishna Nakshatri1,2,3,4, Manjushree Anjanappa1 & Poornima Bhat-Nakshatri1
Recent reports of widespread genetic variation affecting regulation of gene expression raise the 
possibility of significant inter-individual differences in stem-progenitor-mature cell hierarchy in 
adult organs. This has not been explored because of paucity of methods to quantitatively assess 
subpopulation of normal epithelial cells on individual basis. We report the remarkable inter-individual 
differences in differentiation capabilities as documented by phenotypic heterogeneity in stem-
progenitor-mature cell hierarchy of the normal breast. Ethnicity and genetic predisposition are 
partly responsible for this heterogeneity, evidenced by the finding that CD44+/CD24- and PROCR+/
EpCAM- multi-potent stem cells were elevated significantly in African American women compared 
with Caucasians. ALDEFLUOR+ luminal stem/progenitor cells were lower in BRCA1-mutation carriers 
compared with cells from healthy donors (p = 0.0014). Moreover, tumor and adjoining-normal breast 
cells of the same patients showed distinct CD49f+/EpCAM+ progenitor, CD271+/EpCAM- basal, 
and ALDEFLUOR+ cell profiles. These inter-individual differences in the rate of differentiation in 
the normal breast may contribute to a substantial proportion of transcriptome, epigenome, and 
signaling pathway alterations and consequently has the potential to spuriously magnify the extent 
of documented tumor-specific gene expression. Therefore, comparative analysis of phenotypically 
defined subpopulations of normal and tumor cells on an individual basis may be required to identify 
cancer-specific aberrations.
Sequencing-based strategies have enabled better characterization of tumor heterogeneity, particularly in 
breast cancer1,2. However, there have been few attempts to document heterogeneity in normal breast tis-
sue with respect to proportion of stem, progenitor and mature cells at a given time and potential impact 
of this heterogeneity on tumor characterization, particularly for transcriptome analysis. Inter-Individual 
heterogeneity in normal breast tissue due to different rate of differentiation is expected based on recent 
demonstrations that widespread functional variation in transcriptomes between individuals and individ-
ual genotypes could affect the phenotype of normal cells3,4. Standard approaches such as in situ analyses 
and/or microdissection of different epithelial subpopulations and counting number of terminal duct 
lobular units have been used to document heterogeneity in the normal breast5. Recent studies, using 
low-throughput and semi-quantitative immunohistochemistry methods, have identified 11 previously 
undefined cell types in the normal breast based on the expression pattern of the estrogen receptor (ER), 
the androgen receptor, and the vitamin D receptor6. Pregnancy-associated changes in specific cell pop-
ulations and the related risk of developing breast cancer have been investigated using similar methods7.
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Heterogeneity in normal breast can have an influence on cancer stem cell (CSC) characterization. The 
CSC composition of tumors is often determined using cell surface markers such as CD44, CD24, CD271, 
PROCR (CD201), and DNER, or by intracellular staining for markers such as aldehyde dehydrogenase 
using the ALDEFLUOR assay8–10. CD44+ /CD24- and ALDEFLUOR+ cells are the most commonly used 
markers of breast CSCs11,12. Basal/triple-negative breast cancers (TNBCs) show enrichment of CD44+ /
CD24- CSCs, whereas luminal breast cancers are enriched for ALDEFLUOR+ CSCs13–16. All of these 
CSC markers are expressed in normal breast epithelial cells and inter-individual variability in the number 
of normal cells expressing CSC markers would make it difficult to claim CSC enrichment in a tumor 
without characterizing normal cells on an individual basis.
The goals of this study were to document heterogeneity/similarity in profiles of healthy breast tis-
sues, with additional consideration given to ethnicity and genetic predisposition and between tumor and 
tumor-adjacent normal tissue on an individual basis. This process was accomplished by growing cells 
from > 60 primary samples using epithelial reprogramming assay and combinations of nine markers, 
which allowed quantitation of at least 20 cell types on an individual basis17. We used core biopsies of 
healthy breast tissue donated to Komen Tissue Bank as a source of normal breast because of documented 
aberrant histologic characteristics in > 85% of breast tissues obtained from reduction mammoplasty or 
tumor-adjacent normal tissues18. The growth conditions used allowed propagation of stem, progenitor 
and mature cells and the percentage of stem/progenitor/mature cells varied between individuals. We also 
identified two subpopulations of cells that are enriched in women of African American (AA) ancestry 
and specific defects in cells from BRCA1-mutant carriers. Comparative analysis of tumor and normal 
tissue on an individual basis revealed that tumor and adjacent normal cells are phenotypically different in 
the majority of cases. Thus, although not perfect because epithelial cells are out of their natural environ-
ment, the comparison of cells from tumors with the healthy tissue of the contralateral breast or from the 
adjacent normal of the same individual along with healthy tissue of unrelated donors may be necessary 
to discern cancer-specific signaling pathway alterations.
Results
Cells propagated from ~60 primary breast tissues (25 healthy donors, four BRCA1-mutants, three 
BRCA2-mutants, one hypertrophy, one high-risk, nine tumors with seven adjacent normal tissues from 
the same patients, two different tumors in two breasts of the same patient, and different pre-cancerous 
lesions in two breasts of the same patient) were analyzed. These comprehensive analyses documented 
enormous phenotypic heterogeneity in the normal breast, which may be partially influenced by ethnicity. 
Consequently, defining ‘global normal’ for comparative analyses with tumor is extremely difficult.
Phenotypic heterogeneity in the breast epithelial cells of healthy donors. Established mark-
ers of CSCs, as well as recently discovered markers of CSC in glioblastoma, were used to characterize the 
phenotypic heterogeneity of the cells propagated from core breast biopsies of healthy donors using an 
epithelial cell reprogramming assay17. Figure 1A provides percentage of different subpopulation of cells 
present in the breast epithelial cells of seven healthy donors. Additional data on ten other donors can be 
found in Figure S1. Raw flow cytometry pattern of the cells from these individuals are shown in Figures 
S2 and S3. These women differed in age, body mass index (BMI) measurements, and prior pregnancies 
(Table S1). The majority of samples were collected at the luteal phase, and the study included both 
Caucasian (CA) and African American (AA) women. It is critical to note that because cells showed phe-
notypic heterogeneity, the assay system was not biased towards the propagation of specific cell subtypes.
CD44/CD24 staining pattern. CD44 and CD24 are the most commonly used markers to demon-
strate enrichment of CSCs in tumors of specific breast cancer subtypes9,16,19,20. We noted remarkable 
inter-individual variability in the ratio between CD44+ /CD24- and CD44+ /CD24+ normal cells, pos-
sibly reflecting inherent inter-individual differences in the rate of differentiation, irrespective of whether 
samples were collected at luteal or follicular phase (Fig. 1A).
CD49f and EpCAM staining pattern. CD49fhigh/EpCAMlow, CD49fhigh/EpCAMmedium, and CD49flow/
EpCAMhigh cells are considered to be human breast stem (or basal progenitor), luminal progenitor, 
and mature/differentiated cells, respectively21,22. Progenitor and mature populations varied significantly 
between individuals again highlighting differences in the rate of differentiation (Fig. 1A and Figure S1). 
Because previous studies have demonstrated significant differences in gene expression between stem, 
progenitor, and mature cells21,23, inter-individual variation in the ratio between these three cell types 
could potentially interfere with the ability to define global “normal” gene expression.
CD271 and EpCAM staining pattern. CD271+ tumor cells are basal cells with CSC activity and rep-
resent a minor portion of cells in luminal tumors24. The number of CD271+ /EpCAM-, CD271+ /
EpCAM+ , and CD271-/EpCAM+ cells varied significantly between individuals (Fig.  1A and Figure 
S1). At present, the biological differences between CD271+ /EpCAM- and CD271+ /EpCAM+ cells are 
not known, although distinct gene expression differences between the CD271+ /EpCAM- and other epi-
thelial cells have been reported24.
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Jam-A/CD321 and EpCAM staining pattern. The cell adhesion molecule Jam-A/CD321 is expressed 
in the CSCs of glioblastoma but not in the normal brain25. This observation prompted us to evaluate 
whether Jam-A serves as a unique CSC marker in the breast. Unlike in glioblastoma, Jam-A is expressed 
in normal breast, and the staining pattern showed remarkable inter-individual variation. In particular, 
a distinct population of EpCAMhigh/Jam-A+ cells was present in ~50% normal breast tissues (Figures 
S2 and S3).
MUC1 and EpCAM staining pattern. The expression of MUC-1 protein is deregulated in breast cancer 
and is involved in self-renewal26. However, only a few cells were MUC-1+ /EpCAM+ , and they did 
Figure 1. Breast epithelial cells from healthy donors show inter-individual heterogeneity. (A) Cells 
from seven donors were stained with the indicated antibodies, and flow cytometry was used to identify cell 
subpopulations. Percentage of different cell populations is shown. Raw flow cytometry dot-plots are shown 
in Figure S2. (B) Variable number of ALDEFLUOR+ cells among healthy donors.
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not show major inter-individual differences. Thus, not all markers showed significant inter-individual 
heterogeneity.
CD44 and EpCAM staining pattern. CD44 and EpCAM markers have recently been used to distinguish 
luminal and basal cells27. CD44+ /EpCAM- cells are basal cells, whereas CD44-/EpCAM+ or CD44+ /
EpCAM+ cells are luminal cells. Both populations of cells varied significantly between individuals 
(Fig. 1A and Figure S1).
ALDEFLUOR+ staining pattern. Aldehyde dehydrogenase (ALDH)-expressing cells are considered 
breast CSCs, which are often enriched in luminal/HER2+ breast cancers12,15,16. In the normal breast, 
ER+ /ALDH+ progenitor cells are suggested to originate from ER-/ALDH+ stem/progenitor cells, and 
the ALDH1a1 isoform is functionally involved in this lineage specification28. There was considerable 
inter-individual variation in the number of ALDH+ cells (as measured using the ALDEFLUOR assay), 
suggesting that the luminal to basal cell ratio as well as the precursors for ER+ cells vary between indi-
viduals (Fig. 1B, S1 and S4).
Because culturing required growth on irradiated murine embryonic fibroblasts as a feeder layer, we 
ensured that none of these markers was expressed on these fibroblasts (Figure S5A). These cells stained 
weakly for CD49f but not any other markers. We also stained epithelial cells from few samples for CD45, 
CD31, and CD140b, markers of hematopoietic, endothelial, and fibroblast cells, respectively (Figure S5B). 
Less that four percent of cells stained positive for CD45 or CD31. Presence of these small number of 
contaminating lineage positive cells did not influence our interpretation (Figure S5B). Only epithelial 
cells stained positive with a pan-cytokeratin antibody, suggesting that the reprogramming assay promotes 
growth of epithelial cells (representative data are shown in Figure S5C).
CD44high/CD24- cells of AA women express higher levels of genes that regulate stemness, 
EMT, and the extracellular matrix. Among various marker combinations we examined, CD44/
CD24 staining pattern appeared distinct between CA and AA. First, overall number of CD44+ /CD24- 
cells was significantly higher in AA compared with CA (Fig. 2A). Second, cells from several AA donors 
but not CA donors contained a distinct subpopulation of CD44high/CD24- cells (Fig. 2B and Figures S2 
and S3). These CD44high/CD24- cells are distinct from the CD44+ /CD24- cells present in all other sam-
ples based on CD44 expression levels. Thus, ethnicity does appear to have quantitative effect on CD44 
expression.
CD44high/CD24- cancer cells generally overexpress genes associated with stemness and epithelial to 
mesenchymal transition (EMT)13,29. To determine whether AA-specific CD44high/CD24- cells naturally 
express higher levels of these genes, we sorted CD44high/CD24- and CD44+ /CD24+ cells from KTB8 
in three biological replicates and subjected them to qRT-PCR of 84 genes that regulate stemness, cell 
adhesion/invasion, and EMT. The significantly differentially expressed genes between these two subpop-
ulations are shown in Table 1, and the list of genes analyzed with the raw data is in supplementary Table 
S2. We found specific upregulation of select collagens, CTNBB1, FOXC2, and ZEB1 in CD44high/CD24- 
cells. Ingenuity pathway analyses revealed that genes elevated in the CD44high/CD24- cells are part of the 
TGFβ /Wnt CTNBB1/NF-κ B pathway, whereas genes down-regulated in the CD44 high/CD24- cells are 
the part of the p53 and ER pathway (Figure S6). Thus, CD44high/CD24- cells in AA samples may have 
a unique biology.
We found significant overlap between genes differentially expressed in CD44high/CD24- cells and the 
recently described PROCR+ /EpCAM- multi-potent mammary stem cells30. This similarity prompted 
us to determine whether cells from AA-women and CA-women differ in the number of PROCR+ /
EpCAM- cells. Indeed, cells from AA-women that contained CD44high/CD24- subpopulation also showed 
significantly higher numbers of PROCR+ /EpCAM- cells compared with cells from CA-women (n = 7 
for CA and 4 for AA, p = 0.0002; Fig. 2C and Figure S7). These results suggest that AA and CA women 
differ in their breast epithelial cell hierarchy. However, cells prepared from few cryopreserved tissues had 
lower levels of PROCR+ /EpCAM- cells, possibly reflecting sensitivity of these cells to cryopreservation.
BRCA1-mutant carriers contain a lower number of ADLEFLUOR+ breast epithelial cells. To 
determine whether the inter-individual variations noted above are linked to the risk of developing breast 
cancer, we next generated cells from prophylactic mastectomy tissues from various risk groups including 
four BRCA1-mutant carriers and three cases of BRCA2-mutant carriers. In one of the BRCA2-mutant 
carriers, cells from two breasts were independently propagated. Interestingly, there were some differences 
in the levels of differentiated cells between two breasts of the same individual based on CD49f/EpCAM 
staining pattern (Fig. 3A). However, additional samples need to be tested to determine whether there are 
regional differences for undifferentiated and differentiated cells within the breast.
Cells from four BRCA1-mutant carriers showed individual variability and did not display unique 
features compared with healthy donors or other cells from other high-risk patients (Fig.  3A, S8 and 
S9). Previous studies have demonstrated defects in progenitor lineage commitment in BRCA1-mutant 
carriers and enrichment of CD49f+ /EpCAM- basal cells due to the stabilization of the Slug pro-
tein31. We did not observe enrichment of CD49f+ /EpCAM- cells in any of the BRCA1-mutant cases 
compared with healthy donors. In fact, cells from the BRCA1 mutant-4 sample were predominantly 
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CD49f-/EpCAM+ and CD271-/EpCAM+ . Our observation is similar to that in a recent publication 
that failed to observe BRCA1-mutant-specific enrichment of CD49f+ /EpCAM- early basal cells com-
pared with healthy donors32. A specific BRCA1 mutation is less likely to be responsible for this discrep-
ancy because Pathania et al. evaluated cells from 14 types of BRCA1 mutations and did not observe 
Figure 2. Cells derived from AA-women contain unique CD44high/CD24- cells and are enriched for 
PROCR+/EpCAM-cells. (A) Cells derived from AA-women are enriched for CD44+ /CD24- cells compared 
with CA women. (B) Cells from AA-women stained for CD44 and CD24 show a distinct CD44high/CD24- 
cells. Pattern of staining from five CA-women and four AA-women are shown. (C) PROCR/EpCAM staining 
pattern of cells from CA-women and AA-women. The top panel shows PROCR/EpCAM staining pattern 
whereas the bottom panel shows statistical difference in PROCR+ /EpCAM- cells between CA-women and 
AA-women.
www.nature.com/scientificreports/
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differences in CD49f, CD44 and EpCAM expression profiles32. We noted one major difference between 
BRCA1-mutant carriers and healthy donors; all four BRCA1-mutant carriers contained extremely low 
levels of ALDEFLUOR+ cells compared with the seven healthy donors or BRCA2-mutant carriers 
(p = 0.0014 healthy vs. BRCA1-mutants; p = 0.03 BRCA1-mutants vs. BRCA2-mutants, Fig.  3B,C and 
Figure S8). Thus, BRCA1-mutant carriers are likely deficient in precursors for ER+ luminal cells, which 
could explain the higher incidence of TNBCs in BRCA1-mutant carriers.
The BRCA2-mutant carriers demonstrated remarkable inter-individual variability without any unique-
ness (Fig.  3A and S8). Cells from a case of hypertrophy, patient with prior history of breast cancer or 
fibrosis did not display any unique features (Figure S9).
In summation, these results suggest that breast cells from patients at high-risk of developing breast 
cancer display remarkable phenotypic heterogeneity, which is similar to the level of heterogeneity 
observed in the general population. The only exception was lower levels of ALDEFLUOR+ cells in the 
BRCA1-mutant carriers.
CD49f/EpCAM staining identified phenotypically distinct tumor and adjacent normal cells of 
the same patient. Having established individual variation in the normal breast, we next examined 
which of the currently used CSC markers can distinguish tumor from adjacent normal cells and can be 
used to document tumor-specific enrichment of CSCs. We also used this assay to determine whether the 
tumor cell phenotype correlated with clinical parameters. The adjacent normal tissues were from mastec-
tomy cases and from the affected breast as distant away as possible from the tumor without compromis-
ing specimen integrity; all tumors except one HER2+ tumor and one TNBC were from treatment-naïve 
cases. Note that the DNA from a limited number of tumor cells was subjected to copy number variation 
analysis using the NanoString Technology nCounter Cancer CNV v2 code set to confirm genomic aber-
ration in tumor cells. Figure 4 shows quantitative differences in different subpopulation of cells between 
tumor and adjacent normal of seven patients and raw flow cytometry dot-plots are shown in Figure S10. 
Age, ethnicity, and tumor characteristics are shown in Table S3. As with normal breast epithelial cells 
Genes elevated in CD44high/
CD24- cells Fold change P value
1 CAMK2N1 2.63 .041
2 COL3A1 13.86 .041
3 COL5A2 10.03 .046
4 CTNNB1 10.27 .012
5 FOXC2 2.63 .035
6 GSC 6.47 .013
7 IL1RN 19.61 .051
8 ITGAV 6.18 .024
9 PDGFRB 13.55 .017
10 SERPINE1 6.03 .0060
11 SPARC 7.43 .033
12 TGFB1 2.69 .0080
13 TWIST1 8.53 .015
14 WNT5A 6.77 .011
15 ZEB1 5.63 .022
Genes down-regulated in CD44high/CD24- cells
1 CAV2 .21 .017
2 CDH2 .14 .018
3 DSP .13 .015
4 EGFR .44 .007
5 FGFBP1 .23 .051
6 IGFBP4 .44 .031
7 KRT14 .42 .009
8 KRT19 .07 .025
9 PLEK2 .07 .0015
Table 1.  Genes elevated or down-regulated in CD44high/CD24- cells compared with the CD44+/CD24+ 
cells of an AA woman.
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from healthy donors, tumor-adjacent normal showed remarkable heterogeneity. Pair-wise comparison 
also showed different marker profiles of tumor and adjacent normal ranging from modest differences 
(patients 4, 5 and 9) to extreme differences (patients 2, 3 and 6) suggesting differences in differentia-
tion status of tumors and adjacent normal. In general, differentiated tumors contained higher levels of 
CD49f-/EpCAM+ mature cells compared with poorly differentiated tumors.
To further extend the above observations, we characterized tumor cells from two other patients. 
Patient-7 had an ER+ /PR+ moderately differentiated tumor. Tumor cells displayed mature features, 
as most of the tumor cells were CD49flow/EpCAM+ , CD271-/EpCAM+ , and EpCAMhigh/Jam-Ahigh 
Figure 3. BRCA1-mutant carriers have lower ALDEFLUOR+ cells. (A) Breast epithelial cells from four 
BRCA1-mutant carriers and three BRCA2-mutant carriers were stained with antibodies against the indicated 
cell surface markers and subjected to flow cytometry. Inter-individual variation in staining pattern is shown. 
(B) BRCA1-mutant carriers have lower numbers of ALDEFLUOR+ cells compared with cells from healthy 
normal or BRCA2-mutant carriers.
www.nature.com/scientificreports/
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(Figure S11A). The tumor in patient-8 was a TNBC inflammatory type. Tumor cells were predomi-
nantly CD44+ /CD24- and CD49f+ /EpCAM+ (Figure S11B). Additional features of this tumor such 
as enriched CD271+ /EpCAMlow and Jam-A+ /EpCAMlow, cells suggest basal phenotype, which is often 
manifested by inflammatory breast cancers33.
Tumor and adjacent normal cells show different levels of ALDEFLUOR+ cells. To document 
additional differences between the tumor and adjacent normal cells, we stained matched normal and 
tumor cells from five patients with ALDEFLUOR. Based on previous observations14,16, luminal breast 
cancers were expected to demonstrate an elevated number of ALDEFLUOR+ cells compared with adja-
cent normal tissues. However, that did not appear to be the case always. Although the tumor in patient-5 
was a TNBC, her tumor was enriched for ALDEFLUOR+ cells compared with adjacent normal tissue 
(Fig.  5A and Figure S12A). By contrast, the poorly differentiated ER+ /PR+ tumor in patient-6 had a 
lower number of ALDEFLUOR+ cells compared with adjacent normal tissue. Pateint-1 and patient-2 
with differentiated tumors and patient-4 with HER2+ tumor had higher levels of ALDEFLUOR+ cells 
compared with their adjacent normal tissue (Fig.  5A). The ER+ /PR+ tumor of patient-7 had higher 
levels of ALDEFLUOR+ cells compared with the poorly differentiated inflammatory breast cancer of 
patient-8 (Figure S11). Four out of six tumors displayed higher levels of ALDEFLUOR+ cells compared 
with adjacent normal tissue.
Similar to ALDFLUOR, we noted differences in the staining pattern of CD271/EpCAM between tumor 
and adjacent normal with poorly differentiated tumors showing higher levels of CD271+ /EpCAM+ cells 
compared with differentiated tumors (Fig. 5B, Figure S12B). By contrast, Jam-A/EpCAM did not show 
a marked difference between tumor and adjacent normal tissue with the exception of cells from differ-
entiated tumor cells of patient-1 and patient-2 having a distinct Jam-Amedium/EpCAMhigh subpopulation 
(Fig. 5C and Figure S12C).
In summation, the results presented in Figs  4 and 5 indicate that CD49f/EpCAM, ALDEFLUOR, 
and CD271/EpCAM staining are better at distinguishing tumor cells from normal cells on an individual 
Figure 4. Tumor and adjacent normal cells show differences in CD49f and EpCAM staining pattern. 
Tumor and adjacent normal cells from seven patients were stained with isotype control, CD44-APC/
CD24-PE or CD49f-APC/EpCAM-PE and subjected to flow cytometry. The tumor characteristics, age, 
and ethnicity of the patients are shown Table S3. CD44+ /CD24- cells in tumors are suggested to be CSCs. 
CD49f+ /EpCAM-, CD49f+ /EpCAM+ , and CD49f-/EpCAM+ cells are considered to represent stem, 
luminal progenitor, and mature/differentiated cells, respectively. Differentiated tumors contained elevated 
number of CD49f-/EpCAM+ cells, whereas poorly differentiated tumors contained elevated number of 
CD49f+ /EpCAM+ cells. N = normal; T = tumor.
www.nature.com/scientificreports/
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basis. Critically, phenotype of cultured tumor cells showed differentiation characteristics similar to the 
original tumor suggesting the relevance of this culturing method for better characterization of tumors.
Cancer-specific aberrations are involved in conferring phenotypic diversity to tumor 
cells. Although marker expression profiles of tumor cells correlated closely with their pathologist-assigned 
differentiation status, additional proof is needed to show that genomic aberrations are associated with the 
phenotype of these tumor cells. Towards this goal, we characterized two distinct subtypes of tumors from 
the same patient. This AA patient had ER+ /PR+ , node negative multifocal invasive ductal carcinoma 
associated with DCIS in her right breast (DCIS/IDC) and lobular carcinoma in situ (LCIS) in her left 
breast. Previous studies have already documented different molecular aberrations/genetic predisposition 
in LCIS versus IDC34. DCIS/IDC and LCIS cells showed clear differences in their phenotype. For exam-
ple, distinct CD44high/CD24- and CD44high/EpCAM+ subpopulations were present in DCIS/IDC, but 
not in LCIS (Fig. 6A). As noted above, similar CD44high/CD24- cells are present in AA-women. DCIS/
IDC samples contained higher levels of CD44+ /CD24- cells compared with LCIS. DCIS/IDC cells were 
predominantly CD49f+ /EpCAM+ , whereas LCIS had equal levels of CD49f+ /EpCAM+ luminal pro-
genitor and CD49flow/EpCAM+ mature cells (Fig. 6A). Similar differences were noted with respect to the 
CD271 and Jam-A staining patterns, all pointing to more differentiated/luminal features of LCIS com-
pared with DCIS/IDC. Consistent with this possibility, the LCIS sample contained a higher percentage of 
ALDEFLUOR+ cells. The results of another unusual case that involved a right breast with stromal fibro-
sis with microcalcification, whereas the left breast of the same patient with unusual ductal hyperplasia, 
microcalcification and fibroadenomatous change, are shown in Figure S13. CD44/24, CD49f/EpCAM, 
CD44/EpCAM, and ALDEFLUOR staining patterns were different between cells from the two breasts. 
Thus, cancer-specific aberrations contribute to phenotypic changes in the cancer cells.
Both the normal and tumor samples analyzed above were grown on a feeder layer and with ROCK 
inhibitor. Therefore, some of the phenotypic features can be attributed to the growth conditions because 
factors secreted by the feeder layer, or physical contact between epithelial cells and the feeder layer, 
determine the phenotype of the epithelial cells. To rule out this possibility, we adapted DCIS/IDC and 
Figure 5. Tumor and adjacent normal cells show differences in ALDEFLUOR+ cells. (A) The 
ALDEFLUOR staining pattern in tumor and adjacent normal cells from six patients. (B) CD271-APC/
EpCAM-PE staining pattern of tumor and adjacent normal cells. (C) Jam-A-PE/EpCAM-APC staining 
pattern of tumor and adjacent normal cells.
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Figure 6. Two tumor types in the same patient show distinct marker profiles. (A) DCIS/IDC and LCIS 
cells from the same patient grown on a feeder layer display distinct marker profiles. These samples were 
from an AA-woman, and a CD44high/CD24- subpopulation of cells is evident in the DCIS/IDC sample.  
(B) Similar assay as above except that cells were adapted to grow in 2D without a feeder layer for two weeks. 
The 2D condition increased the intensity of the EpCAM staining.
www.nature.com/scientificreports/
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LCIS cells to grow in 2D culture without the feeder layer and ROCK inhibitor and then evaluated cells for 
phenotypic markers. Tumor cells grown under this growth condition were phenotypically similar to cells 
grown on a feeder layer, although cells that were “differentiated” (for example, EpCAMhigh/Jam-Ahigh and 
ALDEFLUOR+ cells) were higher under the 2D culture without the feeder layer (Fig. 6B). Differences 
between DCIS/IDC and LCIS persisted under the 2D growth conditions. Thus, phenotypes observed 
with reprogrammed cells are likely intrinsic properties. Reprogramming growth conditions slow the dif-
ferentiation process and allow for quantification of both undifferentiated/differentiated and basal/luminal 
cells. This is a marked improvement over previously described growth conditions, which, depending on 
growth factors in the media, enrich for either luminal or basal cells35.
Discussion
This study establishes phenotypic heterogeneity in the normal breast, which can be partially attributed to 
ethnicity and genetic susceptibility to breast cancer. We have also documented that tumor and adjacent 
normal cells from the same patient are in different state of differentiation, which could have an impact 
on identifying genes that are causally linked to the disease by differential gene expression analysis. We 
initiated this study to determine the ideal normal breast tissue as a reference because of documented 
histologic abnormalities in reduction mammoplasty or tumor adjacent tissues used routinely as refer-
ence samples18. Although tissues from healthy donors are certainly better than reduction mammoplasty 
samples because there are limited proliferative changes in these tissues, our observation of phenotypic 
heterogeneity with ethnicity as a confounding factor indicates that selection of normal reference breast 
tissues is substantially more complicated than previously envisioned. The best option may be to use 
breast tissues from the contralateral breast for comparative analysis with the tumor on an individual 
basis. However, this is challenging to apply in a clinical setting in the absence of a proven benefit to 
patients. For that reason, we performed all of our tumor-normal pair comparison using tissues from 
complete mastectomy cases, thus allowing us to characterize normal tissue from as far away as possible 
from the tumor.
Ethnicity influences the normal breast hierarchy. Normal breast reference in large-scale studies, 
including TCGA, did not consider ethnicity when selecting tissues36. We observed a unique subpop-
ulation of cells in majority of African American women that are characterized by a higher expression 
of CD44, but lacking CD24 or EpCAM. The difference in this population of cells between AA and CA 
patients is significant (p = 0.01, N = 11 for CA, none positive and N = 10 for AA, 5 positive, Fisher’s exact 
test, two tailed). These cells expressed higher levels of genes associated with stemness and EMT, and 
this expression pattern was markedly similar to genes expressed in PROCR+ /EpCAM- mammary stem 
cells30. Interestingly, all samples that had this unique population were enriched for PROCR+ /EpCAM- 
cells. Because basal cells display the CD44+ /CD24- or the CD44+ /EpCAM- phenotype, and cells with 
these phenotypes often express higher levels of transcription factors involved in EMT13,14,27, it is possible 
that women of AA ancestry have differences in the following: the basal to luminal cell ratio; the rate of 
stem to luminal differentiation; the chromatin organization that permits quick transition between epithe-
lial and mesenchymal states; and consequently a difference in susceptibility to breast cancer. AA-women 
encounter a higher incidence of TNBCs, which are usually enriched for EMT-associated genes37. These 
findings are interesting in the context of recent observation of elevated Wnt, Aurora Kinase A/B, EZH2 
and polo-like kinase signaling networks in TNBCs of AA-women compared with TNBCs of CA-women38. 
It is possible that subpopulation of cells in AA-women naturally have elevated activity of these signaling 
networks and tumors may have originated from such cells. Functional studies of this subpopulation of 
cells may reveal the biology behind TNBCs in AA-women. Mechanistically, elevated levels of PROCR+ /
EpCAM- cells in AA could be related to haplotypes of this gene; there are four haplotypes and H1 among 
them is associated with increased levels of membrane associated PROCR39.
Phenotypic differences between healthy normal and BRCA1-mutant cells. Several breast can-
cer susceptibility genes have been identified over the years but phenotypic markers that can distinguish 
breast epithelial cells of high-risk patients have yet to be identified40. Recent studies with limited number 
of samples showed a defect in luminal progenitor commitment and accumulation of stem cells among 
BRCA1 mutants, which was mechanistically linked to stabilized EMT-associated Slug protein31. However, 
another study failed to observe elevated Slug in BRCA1 mutant cells32. We did observe significantly lower 
ALDEFLUOR+ cells in all BRCA1-mutant samples. Because ALDEFLUOR+ cells are precursors for 
ER+ luminal cells28, future studies may focus on documenting differences in the differentiation of stem/
progenitor cells to mature cells in high-risk patients compared with healthy individuals. In addition, 
differences in ER+ /ALDEFLUOR+ and ER-/ALDEFLUOR+ cells could serve as markers of differenti-
ation defects. Our results differ from other reports, which showed elevated ALDEFLUOR+ cells upon 
BRCA1 knockdown in human breast cancer or epithelial cell lines and in mouse mammary epithelial 
cells41–43. Reasons for this discrepancy are unknown but could be related to differences in source of cells 
(cell lines versus primary cells) and experimental conditions (knockdown versus the presence of mutant 
BRCA1 proteins).
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Impact on studies related to cancer-specific gene expression. In addition to inter-individual 
variation in breast epithelial cells among healthy donors (Fig. 1 and Figure S1), we observed phenotypi-
cally divergent adjoining normal and tumor cells in the same patient. For example, the adjacent normal 
cells from patient-3 contained CD49f-/EpCAM+ mature cells, whereas the tumor cells were mainly lumi-
nal progenitors (Fig. 4). In the case of differentiated tumors (patient-1 and patient-2), the situation was 
reversed. In the normal breast, more than 2000 genes are differentially expressed between differentiated 
luminal and bipotent or luminal-restricted progenitor cells23. Thus, if adjacent normal cells and tumor 
of the same patient differ in their differentiation status, most of the gene expression differences between 
normal and tumor could be the result of variations in differentiation status, and the majority of differ-
entially expressed genes are not causally linked to cancer. This possibility raises concerns about the use 
of resources such as Oncomine and Ingenuity Pathways in assessing cancer-associated gene expression 
changes by comparing cancer with a global “normal” instead of individual-specific “normal”. A recent 
study that utilized single cell RNA-seq further exposed the limitations of current approaches. Although 
RNA-seq analysis of bulk glioblastoma enabled classification of the tumor into a specific subtype, single 
cell RNA-seq showed the presence of alternate subtypes in the same tumor44. Moving forward, it may 
be essential to determine gene expression differences and signaling networks in phenotypically similar 
normal and tumor cells from the same patient.
Materials and Methods
Primary cell propagation. All tissues for the study were de-identified, and Indiana University 
Institutional Review Board considered the protocol as non-human subject research. Tissues were from 
healthy donors or from mastectomy cases. Informed consent was obtained from all subjects. All exper-
iments were carried out in accordance with the approved guidelines. The Komen Tissue Bank collected 
healthy normal tissues, whereas Indiana University Simon Cancer Center (IUSCC) Tissue Bank collected 
tumor and adjacent normal. Standard operating procedure for collecting and processing of normal tissue 
can be found in the Komen Tissue Bank website. For tumors and adjacent normal, a pathologist grossly 
examined each case for size of tumor including inking margins, if necessary, prior to any dissection. 
Normal adjacent or tumor tissue was grossly determined by the pathologist and a representative sec-
tion from each specimen was submitted for Formalin-fixation, paraffin-embedding (FFPE) and Quality 
Control (QC). The normal adjacent tissue was obtained from a distant area of the larger specimen not 
grossly involved with tumor (or margins) and that showed evidence of breast epithelium (i.e. not solely 
adipose tissue). The tissue remaining after QC sections was snap frozen and/or placed in study defined 
nutrient media. A H&E stain was then prepared from each of the FFPE samples and reviewed by a 
pathologist for diagnosis confirmation.
Freshly collected tissues or tissues cryopreserved after mincing and storing in Lonza freezing media 
(Lonza, Basel, Switzerland) with ROCK inhibitor were dissociated using a collagenase/hyaluronidase 
mixture (300 μ l in 2.7 ml of media, Stem Cell Technologies, Vancouver, Canada) plus ROCK inhibitor 
(5 μ M, Lonza) for two hours at 37 °C. The dissociated cells were filtered through sterile 70-micron filters, 
pelleted, washed in PBS, and plated on irradiated murine embryonic fibroblasts (Applied StemCell, Inc., 
San Jose, CA, USA) using the media described previously17 with some modifications. To reduce met-
abolic acidosis, we used a low glucose (1 gm/liter) DMEM and F12 mixture (1:3) and avoided DMSO 
as a solvent for any reagents to reduce stem cell differentiation45. The media additionally contained 
5% fetal bovine serum, 5 μ g/ml of bovine insulin, 0.4 μ g/ml hydrocortisone, and 20 ng/ml EGF and 
penicillin-streptomycin. Irradiated fibroblasts (~400,000) were plated on 60-mm plates in DMEM plus 
10% FBS a day before and washed in PBS before the addition of breast epithelial cells. Tissues that yielded 
multiple colonies were propagated further to avoid analysis of clonally selected cells. The media were 
changed every two days and/or the cells were passaged onto new feeder layer every 2-3 days. The cells 
first were incubated with trypsin at room temperature for 1-2 minutes to remove the feeder layer. After 
washing in PBS, an additional trypsinization was performed at 37 °C for 5–10 minutes. The trypsinization 
time varied from sample to sample and was monitored carefully to ensure full trypsinization. Complete 
trypsinization was necessary for reproducible documentation of the different subtypes of cells. All sam-
ples used in the study were of < 10 passages and were in culture for < 30 days. Several samples were 
analyzed within the second passage, and cells reanalyzed after additional passages were phenotypically 
similar to the cells analyzed earlier. The heterogeneity between samples clearly demonstrates that the 
culture conditions did not favor outgrowth of a specific subpopulation of cells. Cells from nine tumor 
samples, one adjacent normal and one healthy normal were subjected to nCounter® Cancer CNV v2 
evaluation (NanoString Technology) to ensure that tumor cells indeed contained genomic aberration. 
However, contamination of tumor cells with normal breast epithelial cells cannot be ruled out.
Flow cytometry analysis. Cells were stained using the indicated antibodies and were analyzed using 
a BD LSR II flow cytometer, and the data were analyzed using CellQuest or FlowJo software. The anti-
bodies used for the study are listed in Table S4. Forward and Side scatter were used to ensure that only 
live cells were considered in the analysis. Please note that gating was done using appropriate isotype 
control antibodies (included for all three fluorochromes- FITC, PE and APC) and only a representative 
isotype control for two fluorescent markers is shown.
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Human epithelial to mesenchymal transition (EMT) PCR array. CD44high/CD24- and CD44+ /
CD24+ cells from the AA healthy donor (KTB8) were sorted by flow cytometry, and RNA was prepared 
immediately after sorting using the RNAeasy kit (Qiagen, Valencia, CA, USA). To avoid complexity due 
to inter-individual heterogeneity in the genome, cells from the same individual at three different passages 
were sorted, and RNA from biological triplicates was subjected to three independent quantitative reverse 
transcription-polymerase chain reactions (qRT-PCR) using the PCR Array from Qiagen/SA Biosystems 
(catalogue #PAHS-090A). The array contained 84 EMT/differentiation- and development-associated 
genes and five reference genes. All five-reference genes were used for normalization. Table S2 contains 
the list of genes analyzed, the fold changes between the CD44high/CD24- and the CD44+ /CD24+ cells 
and the p values calculated using the computational program provided by the manufacturer.
Statistical analyses. The Graphpad QuickClacs program (Graphpad.com) was used for all statistical 
analyses. Differences in the CD44high/CD24- subpopulation of cells between AA and CA patients were 
analyzed using the Fisher’s exact test (2 × 2 contingency table), whereas an unpaired t test to compare 
between two means was used to analyze differences in PROCR+ /EpCAM- cells between AA-women 
and CA-women and differences in ALDEFLUOR+ cells between BRCA1-mutant patients and healthy 
donors. Average ± standard deviation is shown in figures.
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